Vantage logo

Safety scare knocks Novartis

Heightened Beovu safety concerns could turn into a big problem for Novartis, while rival Regeneron will make the most of any uncertainty.

Vantage logo

Horizon looks for a new growth driver

The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.

Vantage logo

Where now for Oxurion?

The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.